- Primary research
- Open Access
MiR-214 regulate gastric cancer cell proliferation, migration and invasion by targeting PTEN
- Ting-Song Yang†1,
- Xiao-Hu Yang†1,
- Xu-Dong Wang1,
- Yi-Ling Wang1,
- Bo Zhou1 and
- Zhen-Shun Song1Email author
© Yang et al.; licensee BioMed Central Ltd. 2013
- Received: 5 February 2013
- Accepted: 1 July 2013
- Published: 8 July 2013
MicroRNAs are a class of small non-coding RNAs that play an important role in various human tumor initiation and progression by regulating gene expression negatively. The aim of this study was to investigate the effect of miR-214 on cell proliferation, migration and invasion, as well as the functional connection between miR-214 and PTEN in gastric cancer.
miR-214 and PTEN expression was determined in gastric cancer and matched normal tissues, and human gastric cancer cell lines by quantitative real-time PCR. The roles of miR-214 in cell proliferation, migration and invasion were analyzed with anti-miR-214 transfected cells. In addition, the regulation of PTEN by miR-214 was evaluated by Western blotting and luciferase reporter assays.
miR-214 was noted to be highly overexpressed in gastric cancer tissues and cell lines using qRT-PCR. The expression level of miR-214 is significantly associated with clinical progression and poor prognosis according to the analysis of the clinicopathologic data. We also found that the miR-214 levels are inversely correlated with PTEN in tumor tissues. And PTEN expression level is also associated with metastasis and invasion of gastric cancer. In addition, knockdown of miR-214 could significantly inhibit proliferation, migration and invasion of gastric cancer cells. Moreover, we demonstrate that PTEN is regulated negatively by miR-214 through a miR-214 binding site within the 3’-UTR of PTEN at the posttranscriptional level in gastric cancer cells.
These findings indicated that miR-214 regulated the proliferation, migration and invasion by targeting PTEN post-transcriptionally in gastric cancer. It may be a novel potential therapeutic agent for gastric cancer.
- Gastric cancer
Gastric cancer is the second most common cause of cancer-related death worldwide. It has been estimated that approximately 1 million patients are newly diagnosed with gastric cancer worldwide each year, which accounts for nearly 10% of all cancer deaths and claims approximately 700,000 lives annually [1, 2]. Gastric cancer is a complex genetic disease, previous studies have demonstrated that several genes, known as oncogenes or tumor suppressors, were related to the initiation and progression of human gastric cancer , but the common molecular mechanisms of gastric cancer remain to be elucidated.
MicroRNAs, a class of small non-coding 18–25 nt in length RNAs, have been identified that it aberrantly expressed in several human malignancies, and could negatively regulate target gene expression by binding to the 3’-untranslated region (3’-UTR) of mRNAs for translational repression or degradation [4, 5]. In the recent years, mounting evidence suggest that microRNAs plays a essential roles in tumor cell biological processes, such as cell proliferation, differentiation, migration and invasion [6–9].
A recent study determined the relationship between miRNA expression and progression of gastric cancer, which showed that 22 microRNAs were up-regulated, and 13 were down-regulated in gastric cancer, including miR-214 . However, the specific role and molecular mechanism of miR-214 in gastric cancer cells remains unknown. Thus, we investigated the relationship between expression level of miR-214 and clinic pathological feature and prognosis in gastric cancer, and further studied the possible function of miR-214 in the gastric cancer cell line. Our study results show that overexpression of miR-214 is significantly associated with metastasis and invasion and poor prognosis in gastric cancer, moreover, it could negatively regulates PTEN by binding to their 3’-UTR regions to affect gastric cancer cell proliferation, migration and invasion.
Human tissue samples and cell lines
Human tumor tissue samples and adjacent noncancerous controls were obtained by surgical resection from 120 patients with gastric cancer, at Department of General Surgery, Tenth peoples’ hospital, School of Medicine, Tongji University, Shanghai, China. All samples were derived from patients who had not received adjuvant treatment including radiotherapy or chemotherapy prior to surgery. All samples were snap-frozen and stored in liquid nitrogen after collection. Written informed consents were obtained from all subjects, and the study was approved and supervised by the Ethics Committee of Shanghai Tongji university.
The human gastric cancer cell lines SGC-7901, BGC-823 and normal gastric mucosa epithelial cell lines GES-1 were purchased from the Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). Cells were maintained in RPMI1640 (Invitrogen, US) supplemented with 10% fetal bovine serum (Invitrogen, US). All cells were incubated at 37°C in a humidified chamber supplemented with 5% CO2.
RNA extraction and quantitative PCR
Total RNA from tissue sample and cells were isolated using TRIzol reagent (Invitrogen, US). The relative levels of miR-214 were examined by the altered stem-loop RT-PCR with specific RT and PCR primers using U6 snRNA as control. The primers for miR-214 were: Forward primer: 5’-AGCATAATACAGCAGGCACAGAC-3’; Reverse primer: 5’-AAAGGTTGTTCTCCACTCTCTCAC-3’. The expression of PTEN mRNA were detected by quantitative PCR using paired primers. β-actin gene was used as control. The primers for PTEN mRNA were: Forward primer: 5’-ACCAGTGGCACTGTT GTTTCAC-3’; Reverse primer: 5’-TTCCTCTGGTCCTGGTATGAAG-3’.
Quantitative PCR was performed on MX3000P Real-time PCR Instrument (Stratagen, US) using Real-time PCR Universal Reagent (GenePharma, Shanghai) according to the manufacturer’s instructions. The relative expression levels of interest gene were calculated by the 2-ΔΔCt method.
1×106 cells cultured in a well of 6-well cell culture plate were transiently transfected with 50 pmol of miR-214 inhibitor (or control microRNA) and PTEN siRNA oligonucleotide duplexes (or control siRNA) using Lipofectamine 2000 (Invitrogen, US) according to the manufacturer’s protocol, respectively. The sequence used were: 5’-ACUGCCUGUCUGU GCCUGCUGU-3’ (miR-214 inhibitor oligonucleotide); 5’-CAGUACUUUUGUGUAGUAC AA-3’ (control oligonucleotide). Validated siRNAs directed against PTEN and control siRNA were obtained from Cell Signaling. Transfection efficiency was optimized using 6-carboxyfluorescein labeled microRNA (or siRNA) at approximately 80% in gastric cancer cells.
Cell viability assay
We used 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to determine the viability of cells. Cells were seeded in 96-well plates at 8000 cells per well. At the end, cells were incubated in 50 ml of 0.1 mg/ml solution of MTT at 37°C for 4 h and then lysed in 150 ml of dimethylsulfoxide at room temperature for 15 min. Viable cell numbers were estimated by measurement of optical density (OD) at 580 nm at various time points.
Cell population doubling time and cell cycle assay
Cell population doubling time calculation and cell cycle assay were performed as previously described . Cells were seeded into 6-well plates (1 × 104 cells/well) and cultured at 37°C. Cell population doubling time (PDT) was calculated using the following equation: PDT (hr) = (log2×t)/(logNt-logN0), where t=time in culture (hr), Nt = final cell count, N0 = original cell count.
In the cell cycle assay, Cells were fixed in 70% ethanol for 2 hr at 4°C, then, the cells were treated with RNaseA (50 μg/ml) and stained with propidium iodide (25 μg/ml) for 30 min at 37°C. Analyzed all samples using an FACSCalibur flow cytometer (BD Biosciences) and distribution of cell-cycle phases was determined using Modfit Software (BD Biosciences). The proliferative index (PI) was calculated as the percentage of cells in S/G2/M-phase.
Clonogenic assay was also performed as previously described . Single-cell suspension was prepared using trypsin treatment. Cells were then seeded into 6-well cell culture plates (200 cells/well) and incubated for 14 days at 37°C. Then, cells were washed twice with PBS and stained with a mixture of 6.0% glutaraldehyde and 0.5% crystal violet for 1 hour at 37°C. The plates were air dried at room temperature. Colony forming efficiency (CFE) was calculated as the percentage of plated cells that formed colonies.
Cell migration and invasion assay
A cell suspension of in 0.2 ml RPMI-1640 medium with 5% FBS was seeded into each well of the upper Transwell chamber (8-μm pore size, Corning Costar Corp, US), which was pre-coated with or without Matrigel. In the lower chamber, 0.6 ml RPMI 1640 with 20% FBS was added. After incubating for 28 h 37°C in a humidified incubator with 5% CO2, chambers were disassembled and the membranes were stained with 2% crystal violet for 10 min and placed on a glass slide. The number of cells penetrating across membrane were counted under a microscope in ten random visual fields.
Luciferase reporter assay
Dual-luciferase activity assays were performed as previously described . The full-length 3’-UTR segments of PTEN mRNA containing the miR-214 binding site was amplified by PCR and inserted into the Xba1-site of pGL3 vector (Promega, WI) and named pGL3-PTEN. The pGL3-PTEN-mut reporter construct with point mutations in the seed sequence was synthesized using a site-directed mutagenesis kit (Stratagene, CA). Then, 1 × 106 cells were cotransfected with 50 pmol of miR-214 inhibitor (or control miRNA), 1 μg of pGL3-PTEN (or pGL3-PTEN-mut) plasmid, and 1 μg of a Renilla luciferase expression construct pRL-TK (Promega, WI) using Lipofectamine 2000. After 36 h transfection, luciferase activity was measured using the dual luciferase assay system (Promega, WI) and normalized to Renilla luciferase activity.
Cells were washed twice with Hanks’s balanced salt solution and lysed directly in lysis buffer (50 mM Tris–HCl, pH 8.0, 1% NP-40, 10 mM NaCl, 2 mM EDTA, 5 mg/ml leupeptin, 2 mg/ml aprotinin, 2 mg/ml pepstatin, 1 mM DTT, 0.1% SDS and 1 mM phenylmethylsulfonyl fluoride). The protein concentrations of the lysates were measured using a Bradford protein assay kit (Bio-Rad, US). Equivalent amounts of protein were separated by 10% SDS PAGE and then transferred to nitrocellulose membranes by electroblotting. The membranes were blocked with 5% BSA in TBST (10 mM Tris–HCl, pH 8.0, 150 mM NaCl, and 0.05% Tween 20) for 1 hr, and then the membrane was immunoblotted overnight at 4°C with primary antibody, a secondary antibody conjugated with horseradish peroxidase was incubated with the membrane for 1 hr at 37°C. Protein was visualized using enhanced chemiluminescence reagent (Santa Cruz). The expression level of PTEN protein was analyzed using LabWork 4.0 program (UVP) and normalized to that of β-actin protein.
Data are presented as mean ± SEM from at least three independent experiments. Statistical significance was analyzed using SPSS11.0 software package (SPSS Inc., US). The difference between groups was performed with Student’s t-test. Pearson’s correlation was used to estimate the relationship between expression levels of miR-214 and PTEN mRNA. Survival curves were obtained by the Kaplan-Meier method, comparison between curves was calculated by Log-rank test. Differences were considered significant for p-values less than 0.05.
The expression level of miR-214 is up-regulated and inversely correlated with PTEN mRNA in gastric cancer tissues
Association of PTEN mRNA or miR-214 expression with clinicopathological data from gastric cancer patients by quantitative PCR
Relative expression level
Relative mRNA level
≤ 4 cm
> 4 cm
We also examined the expression levels of PTEN mRNA in gastric cancer tissues and normal gastric mucosa tissues. Our results showed that decreased expression of PTEN mRNA was found in gastric cancer tissues (Figure 1C). Furthermore, we found that PTEN mRNA expression was significantly associated with metastasis and TNM stage (Table 1). Across all specimens tested, we found an inverse correlation between the expression of miR-214 and the level of PTEN mRNA (Figure 1D, r=−0.349, P=0.027), but not in normal tissues (Figure 1E, r=−0.026, P=0.641). These data suggest that miR-214 may be involved in the regulation of PTEN in gastric cancer.
Knockdown of miR-214 could inhibit the proliferation, migration and invasion of gastric cancer cell lines
miR-214 post-transcriptionally down-regulates PTEN expression by targeting the 3’ untranslated region of PTEN
We further determined the expression of PTEN protein and mRNA by Western blotting and qRT-PCR in gastric cancer cells transfected with anti-miR-214 (or control anti-miRNA). As shown in Figure 3C and 3D, the expression of PTEN protein was significantly increased in cells transfected with anti-miR-214 as compared to the cells treated with control anti-miRNA at 48 hr post-transfection. However, the expression of PTEN mRNA showed no significant difference between the two groups (Figure 3E). These results indicate that the 3’-UTR of PTEN mRNA is a functional target of miR-214 in gastric cancer cells.
Down-regulation of PTEN could significantly attenuated the inhibitory effects of anti-miR-214 on the proliferation, migration and invasion of gastric cancer cell lines
Recent several studies shown the dysregulation of some miRNAs in various types of human cancers, and the alteration of miRNAs expression might contribute to human carcinogenesis by regulating multiple types of target genes expression [13–15]. Hence, identification of specific miRNAs and their targets involved in tumorigenesis would provide valuable insight for the diagnosis and therapy of patients with human malignancies. Here, we have demonstrated that knockdown of miR-214 could inhibit proliferation, migration and invasion capacity of gastric cancer cells by negatively regulating tumor suppressor PTEN at the post-transcriptional level via binding to non-coding regions of PTEN. Our study data suggest that miR-214 may be useful as a novel potential therapeutic approach for the treatment of gastric cancer.
It was previously reported that miR-214 is involved in the murine aging process , modulates Hedgehog signaling to specify muscle cell fate , and induces cell survival and cisplatin resistance by targeting PTEN in human ovarian cancer . In addition, miR-214 expression was elevated in pancreatic cancer tissues compared with matched benign pancreatic tissues, and overexpression of miR-214 could decreased the sensitivity of the pancreatic cancer cells to gemcitabine by targeting ING4 mRNA . Meanwhile, miR-214 is down-regulated in human cervical cancer tissue compared with normal tissue and that it negatively regulates HeLa cell proliferation by targeting the noncoding regions of MEK3 and JNK1 mRNAs . In the present study, we found that the expression level of miR-214 was up-regulated in gastric cancer tissue compared with matched normal tissue, and miR-214 expression level was significantly associated with clinical progression and poor prognosis. Specially, we found that the proliferative, migratory and invasive capacity of gastric cancer cells transfected with anti-miR-214 was significantly lower than that of cells transfected with control anti-miRNA, suggesting that repressing miR-214 expression could inhibit the proliferative and progressive capacity of gastric cancer cells.
PTEN is a protein tyrosine phosphatase and tensin homologue, which was first discovered by independent laboratories and identified as a tumor suppressor gene located on human chromosome region 10q23 . It has been reported that PTEN makes a great contribution to cellular apoptosis, proliferation, migration and invasion, as well as angiogenesis through interference with several signaling pathways [21–24]. Recent studies have shown that PTEN protein expression frequently is decreased or absent in human gastric cancer. Moreover, decreased PTEN expression correlates with differentiation, growth, progression and angiogenesis in gastric cancer [25, 26]. In addition, up-regulation of PTEN can increase expression of Caspase-3 to make tumor cells apoptosis disorder, which forms molecular mechanisms of PTEN contribution to tumorigenesis and progression of gastric cancer .
In this study, we confirmed that PTEN is down-regulated in gastric cancer in vivo, consistent with the previous findings. Moreover, the expression of PTEN is positively correlated with metastasis and invasion from the clinicopathologic data analysis. In addition, we observed a highly significant negative correlation between miR-214 and PTEN expression in tumor tissues, suggesting that miR-214 could be involved in the regulation of PTEN in gastric cancer. Combining with the target reporter assays, we further have demonstrated that miR-214 post-transcriptionally regulates PTEN via binding the 3’-UTR of PTEN mRNA. Considering the different miRNA have different roles and target genes in different tumors, so we have choosed two gastric cancer cell lines as a model to validated the regular effects of miR-214 on PTEN gene.
In summary, we have demonstrated that miR-214 is overexpressed in gastric cancer, and knockdown of miR-214 can significantly inhibit the proliferation, migration and invasion capacity of gastric cancer cell through the PTEN-mediated signal pathway, which has not been documented in previous studies. Our data suggest that miR-214 is possible to become a potential therapeutic agent for gastric cancer.
This work is supported in part by National Nature Science Foundation of China (No. C30672046).
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics, 2011. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.View ArticlePubMedGoogle Scholar
- Brenner H, Rothenbacher D, Arndt V: Epidemiology of stomach cancer. Methods Mol Biol. 2009, 472: 467-477. 10.1007/978-1-60327-492-0_23.View ArticlePubMedGoogle Scholar
- Tamura G: Alterations of tumor suppressor and tumor related genes in the development and progression of gastric cancer. World J Gastroenterol. 2006, 12: 192-198.PubMed CentralPubMedGoogle Scholar
- Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R: Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006, 20: 515-524. 10.1101/gad.1399806.View ArticlePubMedGoogle Scholar
- Hobert O: Gene regulation by transcription factors and microRNAs. Science. 2008, 319: 1785-1786. 10.1126/science.1151651.View ArticlePubMedGoogle Scholar
- Ahmed FE: Role of miRNA in carcinogenesis and biomarker selection: a methodological view. Expert Rev Mol Diagn. 2007, 7: 569-603. 10.1586/14737184.108.40.2069.View ArticlePubMedGoogle Scholar
- Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007, 133: 647-658. 10.1053/j.gastro.2007.05.022.PubMed CentralView ArticlePubMedGoogle Scholar
- Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M, Baba H: MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res. 2009, 15: 1915-1922. 10.1158/1078-0432.CCR-08-2545.View ArticlePubMedGoogle Scholar
- Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, Nabae T, Takahata S, Toma H, Nagai E, Tanaka M: MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther. 2009, 8: 1067-1074. 10.1158/1535-7163.MCT-08-0592.View ArticlePubMedGoogle Scholar
- Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM: Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11: 136-146. 10.1016/S1470-2045(09)70343-2.PubMed CentralView ArticlePubMedGoogle Scholar
- Yuan Y, Zeng ZY, Liu XH, Gong DJ, Tao J, Cheng HZ, Huang SD: MicroRNA-203 inhibits cell proliferation by repressing ΔNp63 expression in human esophageal squamous cell carcinoma. BMC Cancer. 2011, 11: 57-10.1186/1471-2407-11-57.PubMed CentralView ArticlePubMedGoogle Scholar
- Tang H, Tang XY, Liu M, Li X: Targeting alpha-fetoprotein represses the proliferation of hepatoma cells via regulation of the cell cycle. Clin ChimActa. 2008, 394: 81-88. 10.1016/j.cca.2008.04.012.View ArticleGoogle Scholar
- Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ: MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008, 68: 425-433. 10.1158/0008-5472.CAN-07-2488.View ArticlePubMedGoogle Scholar
- He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM: A microRNA polycistron as a potential human oncogene. Nature. 2005, 435: 828-833. 10.1038/nature03552.PubMed CentralView ArticlePubMedGoogle Scholar
- Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006, 103: 2257-2261. 10.1073/pnas.0510565103.PubMed CentralView ArticlePubMedGoogle Scholar
- Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006, 6: 259-269.View ArticlePubMedGoogle Scholar
- Maes OC, An J, Sarojini H, Wang E: Murine microRNAs implicated in liver functions and aging process. Mech Ageing Dev. 2008, 129: 534-541. 10.1016/j.mad.2008.05.004.View ArticlePubMedGoogle Scholar
- Flynt AS, Li N, Thatcher EJ, Solnica-Krezel L, Patton JG: Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate. Nat Genet. 2007, 39: 259-263. 10.1038/ng1953.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol. 2010, 3: 46-10.1186/1756-8722-3-46.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, Liu T, Tang H: MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 2009, 61: 1075-1082. 10.1002/iub.252.View ArticlePubMedGoogle Scholar
- Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997, 275: 1943-1947. 10.1126/science.275.5308.1943.View ArticlePubMedGoogle Scholar
- Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP: Redox regulation of PI3-kinase signalling via inactivation of PTEN. EMBO J. 2003, 22: 5501-5510. 10.1093/emboj/cdg513.PubMed CentralView ArticlePubMedGoogle Scholar
- Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm JB, Zumstein L, Watson GJ, Snary D, Roth JA, Grimm EA, Ramesh R, Chada S: PI3K blockade by Ad-PTEN inhibits invasion and induces apoptosis in radial growth phase and metastatic melanoma cells. Mol Med. 2002, 8: 451-461.PubMed CentralPubMedGoogle Scholar
- Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998, 280: 1614-1617. 10.1126/science.280.5369.1614.View ArticlePubMedGoogle Scholar
- Castellino RC, Durden DL: Mechanisms of disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007, 3: 682-693.View ArticlePubMedGoogle Scholar
- Yang L, Kuang LG, Zheng HC, Li JY, Wu DY, Zhang SM, Xin Y: PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma. World J Gastroenterol. 2003, 1: 35-39.Google Scholar
- Zheng HC, Li YL, Sun JM, Yang XF, Li XH, Jiang WG, Zhang YC, Xin Y: Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products. World J Gastroenterol. 2003, 9: 1662-1666.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.